Emotional blunting in patients with depression. Part IV: differences between patient and physician perceptions

Michael Cronquist Christensen; Hongye Ren; Andrea Fagiolini

doi:10.1186/s12991-022-00391-5

Emotional blunting in patients with depression. Part IV: differences between patient and physician perceptions

Ann Gen Psychiatry. 2022 Jun 22;21(1):22. doi: 10.1186/s12991-022-00391-5.

Authors

Michael Cronquist Christensen¹, Hongye Ren², Andrea Fagiolini³

Affiliations

¹ H. Lundbeck A/S, Medical Affairs, Ottiliavej 9, 2500, Valby, Denmark. MCRC@lundbeck.com.
² H. Lundbeck A/S, Medical Affairs, Ottiliavej 9, 2500, Valby, Denmark.
³ Division of Psychiatry, Department of Molecular and Developmental Medicine, University of Siena School of Medicine, Siena, Italy.

Abstract

Background: Emotional blunting is common in patients with depression. An online survey was undertaken to assess the experience of emotional blunting, and its impact on functioning and quality of life, in the acute and remission phases of depression from the perspective of patients and healthcare providers (HCPs). This paper presents data on the level of concordance between patient and HCP perspectives.

Methods: This was a cross-sectional, observational study. Patient respondents were adults with a diagnosis of depression, who were currently using a prescribed antidepressant, and who reported emotional blunting during the past 6 weeks. HCPs completed the survey for the last two eligible patients they had seen, one in each phase of depression. Assessments included the Oxford Depression Questionnaire (ODQ) 'antidepressant as cause' domain and the Functioning Assessment Short Test (FAST).

Results: Mean ODQ 'antidepressant as cause' domain scores were significantly higher in the patient-reported cohort (n = 752) than in the HCP-assessed cohort (n = 766) in both the acute (18.0 vs 12.5, respectively; p < 0.01) and remission phases (17.6 vs 12.6; p < 0.01). Overall, 45% of patients believed that their antidepressant medication was negatively affecting their emotions and 39% were considering stopping or had stopped their antidepressant because of perceived emotion-related side effects. In the HCP-assessed cohort, the antidepressant was considered responsible for emotional blunting in 30% of patients and only 18% of patients were believed to be considering stopping their medication due to emotional blunting. Patients reported a greater impact of emotional blunting on activities of daily living than HCPs. Mean FAST score was significantly higher in each phase of depression in the patient-reported cohort than in the HCP-assessed cohort (acute phase, 47.0 vs 39.1; remission phase, 33.5 vs 19.4; both p < 0.01).

Conclusions: Compared with previous studies, our results suggest that HCPs may underestimate the prevalence of emotional blunting in patients with depression. HCPs also appear to underestimate the severity and impact of emotional blunting on patient functioning and treatment adherence compared with patients' own perspectives. Differences between patient and HCP perspectives were most pronounced during the acute phase of the disease.

Keywords: Depression; Emotional blunting; Functioning; Healthcare provider perspectives; Oxford Depression Questionnaire; Patient perspectives; Treatment phase.